FDMT
4D Molecular Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.97
+1.84%Next report
Analyst consensus
- Next report date
- Nov 10, 2026
- EPS estimate
- -$1.04
- Revenue estimate
- $3.5M
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$1.04
- EPS estimate
- -$1.02
- Revenue actual
- $3.8M
- Revenue estimate
- $3.6M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 8
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +43.2%
- Revenue beats (12Q)
- 4
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $37
- PT range
- $36 – $37
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 10, 2026